UBA1 enhances phagocytosis by suppressing CD47 expression in small cell lung cancer
Frontiers in Oncology · 20.08.2026 · 16
DOI: 10.3389/fonc.2026.1838900 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 20.08.2026. Verfasst von Dongyun Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University …. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Small cell lung cancer (SCLC) exhibits a limited overall response rate to immunotherapy, largely due to its highly immunosuppressive microenvironment. CD47, an innate immune checkpoint frequently overexpressed on SCLC cells, contributes to immune evasion by inhibiting macrophage-mediated phagocytosis. Here, we uncover a previously unrecognized immunoregulatory function of ubiquitin-like modifier activating enzyme 1 (UBA1) in SCLC.
Methods
We analyzed UBA1 expression in 16 SCLC patients undergoing immunotherapy (immunohistochemistry). Functional studies used UBA1-knockdown and overexpression SCLC cell lines (H446, H82) to assess phagocytosis, macrophage polarization, and CD47 regulation. Mechanistic insights were obtained via Hippo pathway activation assays (enhancing MST1/YAP phosphorylation). In vivo subcutaneous xenografts in nude mice evaluated tumor growth and macrophage infiltration.
Results
High UBA1 expression correlated with improved immunotherapy response and prolonged progression-free survival. UBA1 activates the Hippo signaling pathway, enhancing MST1 and YAP phosphorylation and thereby repressing CD47 transcription. UBA1 overexpression attenuates surface CD47 levels in SCLC cells, potentiates macrophage phagocytic activity, and promotes a pro-inflammatory macrophage polarization, whereas UBA1 knockdown exerts opposing effects. In vivo xenograft models further confirm that UBA1 deficiency diminishes tumor susceptibility to phagocytosis and accelerates tumor progression.
Conclusion
UBA1 enhances phagocytosis by suppressing CD47 through the Hippo-YAP pathway, improving immunotherapy efficacy in SCLC. Collectively, these findings reveal that the UBA1-CD47 axis represents a potentially pathway in SCLC and UBA1 may serve as a candidate biomarker and a potential mechanistic node for therapeutic intervention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- Kindstar Global Precision Medicine Institute, Wuhan, China.
- Department of Hepatobiliary Surgery, Fengjie County People's Hospital of Chongqing, Chongqing, China.
- Department of Hepatobiliary Surgery, Fengjie Hospital, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zitieren
APA
Li, D., Li, N., Liu, Y., Chen, J., Wang, Z., Chen, L., Wu, H., & Lan, H. (2026). UBA1 enhances phagocytosis by suppressing CD47 expression in small cell lung cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1838900
Vancouver
Li D, Li N, Liu Y, Chen J, Wang Z, Chen L, et al. UBA1 enhances phagocytosis by suppressing CD47 expression in small cell lung cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1838900
BibTeX
@article{Li2026,
author = {Li, Dongyun and Li, Na and Liu, Yiqiang and Chen, Junyang and Wang, Zongding and Chen, Lei and Wu, Hong and Lan, Haitao},
title = {UBA1 enhances phagocytosis by suppressing CD47 expression in small cell lung cancer},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1838900}
}
EUVIMED